Multidrug-Resistant Enterococcus faecium Endocarditis Treated with Combination Tigecycline and High-Dose Daptomycin

Abstract

Spanish

French

Objective:

To report a case of multidrug-resistant Enterococcus faecium requiring combination antibacterial therapy,

Case Summary:

A 39-year-old female presented with chest pain and a history of endocarditis 3 years prior to admission. Blood cultures were positive for E. faecium. She was treated initially with daptomycin 6 mg/kg daily, which was later increased to 8 mg/kg daily despite poor gentamicin clearance. A variety of antibiotics were used in combination with daptomycin, but the patient remained febrile, with positive blood cultures revealing vancomycin minimum inhibitory concentration (MIC) greater than 256 μg/mL and daptomycin MIC 3 μg/mL (and later, 4 μg/mL). Following the addition of tigecycline, the patient experienced rapid clinical and microbiologic improvement, and blood cultures remained negative 9 weeks after discharge.

Discussion:

Limited clinical data support the use of daptomycin for the treatment of E. faecium endocarditis, and information regarding the effects of escalating doses and combination therapy is scant. After failing multiple combination regimens, this patient responded to a combination of tigecycline and daptomycin. Daptomycin 8 mg/kg daily did not result in creatine kinase elevation in the face of evidence of possible renal dysfunction.

Conclusions:

Increasing doses of daptomycin may enhance efficacy without compromising safety, even in patients with some renal dysfunction. The combination of daptomycin and tigecycline may be useful for the treatment of multidrug-resistant E. faecium.

Keywords

daptomycin endocarditis Enterococcus tigecycline

Get full access to this article

View all access options for this article.

References

Centers for Disease Control and Prevention. Nosocomial enterococci resistant to vancomycin-United States, 1989-1993. MMWR Morb Mortal Wkly Rep 1993;42:597–9.

Waites

, Duffy

, Dowzicky

. Antimicrobial susceptibility among pathogens collected from hospitalized patients in the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial. Antimicrob Agents Chemother 2006;50:3479–84. DOI 10.1128/AAC.00210-06

Rybak

. The efficacy and safety of daptomycin: first in a new class of antibiotics for gram-positive bacteria. Clin Microbiol Infect 2006;12:24–32. DOI 10.1111/j.1469-0691.2006.01342.x

Oleson

, Berman

, Kirkpatrick

, Regan

, Lai

, Tally

. Once-daily dosing in dogs optimizes daptomycin safety. Antimicrob Agents Chemother 2000;44:2948–53.

Cha

, Rybak

. Daptomycin against multiple drug-resistant Staphylococcus and Entervcoccus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. Diagn Microbiol Infect Dis 2003;47:539–46. DOI 10.1016/S0732-8893(03)00119-6

Akins

, Rybak

. Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptides: intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcusfaecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 2001;45:454–9. DOI 10.1128/AAC.45.2.454-459.2001

Cha

, Grucz

, Rybak

. Daptomycin dose-effect relationship against resistant gram-positive organisms. Antimicrob Agents Chemother 2003;47:1598–603. DOI 10.1128/AAC.47.5.1598-1603.2003

Dvorchik

, Brazier

, DeBruin

, Arbeit

. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy volunteers. Antimicrob Agents Chemother 2003;47:1318–23. DOI 10.1128/AAC.47.4.1318-1323.2003

Benvenuto

, Benziger

, Yankelev

, Vigliani

Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Chemother 2006;50:3245–9. DOI 10.1128/AAC.00247-06

10.

Durack

, Lukes

, Bright

. New criteria for diagnosis of infective endocarditis: utilization of specific echocardiographic findings. Duke Endocarditis Service. Am J Med 1994;96:200–9.

11.

Dandekar

, Tessier

, Williams

. Pharmacodynamic profile of daptomycin against Emerococcus species and methicillin-resistant Staphylococcus aureus in a murine thigh infection model. J Antimicrob Chemother 2003;52:405–11. DOI 10.1093/jac/dkg337

12.

Figueroa

, Mangini

, Amodio-Groton

. Clinical safety with daptomycin at doses greater than 6 mg/kg (poster A-792). Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 17-20, 2007, Chicago, IL.

13.

Figueroa

, Mangini

, Amodio-Groton

. Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program. Clin Infect Dis 2009;49:177–80. DOI 10.1086/600039

14.

Alam

, Jimenez

Daptomycin for the treatment of persistent VRE bacteremia and/or IE that failed to respond to current therapeutics (poster 1088.15). Presented at: 45th Annual Meeting of the Infectious Disease Society of America, October 4-7, 2007, San Diego, CA.

15.

Moise

, Hershberger

, Amodio-Groton

, Lamp

. Safety and clinical outcomes when utilizing high-dose (≥8 mg/kg) daptomycin therapy. Ann Pharmacother 2009;43:1211–9. Epub 7 Jul 2009. DOI 10.1345/aph.1M085

16.

Levine

, Lamp

. Daptomycin in the treatment of patients with infective endocarditis: experience from a registry. Am J Med 2007;120(10 suppl 1):S28–33. DOI 10.1016/j.amjmed.2007.07.011

17.

Arias

, Torres

, Singh

. Failure of daptomycin monotherapy for endocarditis caused by an Enterococcus faecium strain with vancomycin-resistant and vancomycin-susceptible subpopulations and evidence of in vivo loss of the vanA gene cluster. Clin Infect Dis 2007;45:1343–6. DOI 10.1086/522656

18.

Segreti

, Crank

, Finney

. Daptomycin for the treatment of gram-positive bacteremia and infective endocarditis: a retrospective case series of 31 patients. Pharmacotherapy 2006;26:347–52. DOI 10.1592/phco.26.3.347

19.

Schwartz

, Ngo

, Guglielmo

. Daptomycin treatment failure for vancomycin-resistant Enterococcusfaecium infective endocarditis: impact of protein binding (letter)? Ann Pharmacother 2008;42:289–90. Epub 2 Jan 2009. DOI 10.1345/aph.1K548

20.

Stein

, Craig

. Tigecycline: a critical analysis. Clin Infect Dis 2006;43:518–24. DOI 10.1086/505494

21.

Pfaller

, Sader

, Jones

. Evaluation of the in vitro activity of daptomycin against 19615 clinical isolates of gram-positive cocci collected in North American hospitals (2002-2005). Diagn Microbiol Infect Dis 2007;57:459–65. DOI 10.1016/j.diagmicrobio.2006.10.007

22.

Performance standards for antimicrobial susceptibility testing; seventeenth information supplement. Wayne, PA: Clinical and Laboratory Standards Institute, 2007:26(1).

23.

Pankey

, Ashcraft

, Patel

In vitro synergy of daptomycin plus rifampin against Enterococcus faecium resistant to both linezolid and vancomycin. Antimicrob Agents Chemother 2005;49:5166–8. DOI 10.1128/AAC.49.12.5166-5168.2005

24.

Rand

, Houck

Daptomycin synergy with rifampicin and ampicillin against vancomycin-resistant enterococci. J Antimicrob Chemother 2004;53:530–2. DOI 10.1093/jac/dkh104

25.

Snydman

, McDermott

, Jacobus

. Evaluation of in vitro interaction of daptomycin with gentamicin or beta-lactam antibiotics against Staphylococcus aureus and enterococci by FIC index and timed-kill curves. J Chemother 2005;17:614–21.

26.

Cilli

, Aydemir

, Tunger

In vitro activity of daptomycin alone and in combination with various antimicrobials against gram-positive cocci. J Chemother 2006;18:27–32.

27.

Jenkins

Linezolid- and vancomycin-resistant Enterococcusfaecium endocarditis: successful treatment with tigecycline and daptomycin. J Hosp Med 2007;2:343–4. DOI 10.1002/jhm.236